HealthyNCT06931977
Natural Product System and Lifestyle Modification
A study testing Supplement system + copaiba softgels in people with Healthy, run by dōTERRA International at 1 site in United States.
Trial summary
The goal of this clinical trial is to learn whether four dietary supplements and lifestyle changes can affect gene expression and blood markers in healthy volunteers. The main questions it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 30 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Supplement system + copaiba softgels
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 97 participants
- Where
- 1 siteUnited States
- Study dates
- 29 Apr 2025to 3 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Adults ages 30-55 years old
- Willing to attend three study visits at Prime Meridian Health Clinic in Pleasant Grove, Utah
- Willing and able to undergo three blood draws over 12 weeks
- Willing to provide urine and stool samples three times over 12 weeks
- Willing to wash out of all internally consumed essential oils or botanical products for at least 2 weeks prior to starting the study, and willing to maintain the washout for the duration of the study (14 weeks).
- Willing to wash out of all fish oil supplements, probiotic supplements, and greens powder mix 2 weeks prior to starting the study, and willing to maintain the washout for the duration of the study (14 weeks).
Show all 24Show fewer
- Willing and able to consume study product as directed daily for about 12 weeks
- Willing to track consumption of study product
- Willing to implement changes to diet, exercise, and sleep habits for 12 weeks
- Willing to avoid alcohol, recreational drugs, and smoking/vaping for the duration of the study (approximately 12 weeks)
- Own a smartphone or tablet and willing to download the fitness tracker app
- Willing to wear a fitness tracker for the duration of the study (approximately 12 weeks)
- At least 110 pounds
- No metabolic disease (BMI>35, diagnosis and treatment of
- hypertension, diabetes, or dyslipidemia)
- No major diseases under treatment by doctor (Medical Reviewer's
- discretion)
- No pregnancy within the last 60 days or currently breastfeeding
- (females)
- No allergy to any of the ingredients in the study products
- No regular internal consumption of the study products within the last 1 month (regularly is defined as dosing daily for more than 2 consecutive weeks, or dosing more than 2-3 times per week for 4 consecutive weeks)
- No alcohol, recreational drug, or smoking/vaping use in the past 1 month
- No evidence of medical condition, significant disease or disorder, medication, or surgery within the past 12 months that may, in the judgment of the medical provider, put the participant at risk or affect study results, procedures, or outcomes
- Not currently or previously participating in any other clinical trial within the last 30 calendar days
Who cannot join
- Failure to meet all listed inclusion criteria
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Wellness and Epigenetic Impact of a Natural Product Supplement System Combined With Lifestyle Modification
The goal of this clinical trial is to learn whether four dietary supplements and lifestyle changes can affect gene expression and blood markers in healthy volunteers. The main questions it aims to answer are:
- How does daily ingestion of dietary supplements affect gene expression and hsCRP and vitamin D levels measured in blood?
- How does daily ingestion of dietary supplements affect anthropometric measurements, sleep and physical activity, and gut microbiome composition?
- How does daily ingestion of dietary supplements affect cognitive and subjective health parameters?
- Do prescriptive lifestyle modifications affect the supplements' efficacy?
- Is there a difference in outcomes between participants who take all four study supplements and those who take three study supplements with a placebo?
- Is ingesting dietary supplements for 12 weeks safe, as measured by laboratory tests and adverse events?
Read the detailed description
This double-blind, repeated measures study will recruit healthy adults to determine efficacy, safety, anthropometric, microbiome, and epigenetic effects of consuming four dietary supplements daily for 12 weeks. Prescriptive lifestyle modifications (diet, exercise, and sleep) will be evaluated with the supplement use.
- Conditions
- Healthy
- Being tested
- Supplement system + copaiba softgels, Supplement system + placebo softgels
- Keywords
- Gene expression, Essential oil, Copaiba, Omega 3, Probiotic, Greens powder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Supplement system + copaiba softgelsDietary supplement
The supplement system consists of:
- dōTERRA VMG+ Whole-Food Nutrient Complex (VMG) sachets
- dōTERRA EO Mega+ Essential Oil Omega Complex (EOM) softgels
- dōTERRA PB Restore ProBiome Complex (PBR) capsules
Which will also be taken with:
- dōTERRA Copaiba Essential Oil (CEO) softgels
VMG is a powdered nutritional drink packaged in individual sachets. The powder is a blend of food powders/extracts, vitamins and minerals, probiotics, essential oils, and sweeteners.
EOM is a softgel containing fish oil and wild orange essential oil.
PBR is a capsule containing a mix of pre-, pro-, and post-biotics and bacteriophages.
CEO is a softgel containing Copaifera (copaiba) essential oil and extra virgin olive oil.
Participants will also be asked to implement lifestyle changes. They will be asked to try to get at least 8 hours of sleep, eat at least three servings of fruit/vegetables daily, and exercise at least 30 minutes every day.
Supplement system + placebo softgelsDietary supplement
The supplement system consists of:
- dōTERRA VMG+ Whole-Food Nutrient Complex (VMG) sachets
- dōTERRA EO Mega+ Essential Oil Omega Complex (EOM) softgels
- dōTERRA PB Restore ProBiome Complex (PBR) capsules
Which will also be taken with:
- Olive oil placebo softgels
VMG is a powdered nutritional drink packaged in individual sachets. The powder is a blend of food powders/extracts, vitamins and minerals, probiotics, essential oils, and sweeteners.
EOM is a softgel containing fish oil and wild orange essential oil.
PBR is a capsule containing a mix of pre-, pro-, and post-biotics and bacteriophages.
The placebo is a softgel containing extra virgin olive oil.
Participants will also be asked to implement lifestyle changes. They will be asked to try to get at least 8 hours of sleep, eat at least three servings of fruit/vegetables daily, and exercise at least 30 minutes every day.
| Study group | Role | What they receive |
|---|---|---|
| Supplement System + Copaiba softgels | Experimental | Participants in this arm will take one VMG sachet, three EOM softgels, and one copaiba softgel in the morning with food. At least eight hours later, they will take one PBR capsule and one copabia softgel with food. They will follow this dosing regimen every day for 12 weeks. Receives: Dietary Supplement: Supplement system + copaiba softgels |
| Supplement System + placebo softgels | Placebo comparator | Participants in this arm will take one VMG sachet, three EOM softgels, and one placebo softgel in the morning with food. At least eight hours later, they will take one PBR capsule and one placebo softgel with food. They will follow this dosing regimen every day for 12 weeks. Receives: Dietary Supplement: Supplement system + placebo softgels |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gene expression
Gene expression analysis refers to a genome-wide quantification of methylation. EPIC850k array will be used for methylation analysis. This represents approximately 900,000 gene locations. The main feature performed is a differential methylation analysis to determine what has significantly changed from one time point to another.
Measured: 12 weeks
Vitamin D 25-hydroxy (ng/mL)
Serum marker for Vitamin D levels
Measured: 12 weeks
High sensitivity C-reactive protein (mg/L)
Serum marker for hsCRP levels
Measured: 12 weeks
Secondary outcomes (68)
Albumin (g/dL)
Item in comprehensive metabolic panel for safety assessment
Measured: 12 weeks
Blood urea nitrogen (BUN) (mg/dL)
Item in comprehensive metabolic panel for safety assessment
Measured: 12 weeks
Creatinine (mg/dL)
Item in comprehensive metabolic panel for safety assessment
Measured: 12 weeks
Alkaline phosphatase (U/L)
Item in comprehensive metabolic panel for safety assessment
Measured: 12 weeks
Alanine transaminase (ALT) (U/L)
Item in comprehensive metabolic panel for safety assessment
Measured: 12 weeks
Aspartate aminotransferase (AST) (U/L)
Item in comprehensive metabolic panel for safety assessment
Measured: 12 weeks
Calcium (mg/dL)
Item in comprehensive metabolic panel for safety assessment
Measured: 12 weeks
Carbon Dioxide (mmol/L)
Item in comprehensive metabolic panel for safety assessment
Measured: 12 weeks
Chloride (mmol/L)
Item in comprehensive metabolic panel for safety assessment
Measured: 12 weeks
Potassium (mmol/L)
Item in comprehensive metabolic panel for safety assessment
Measured: 12 weeks
Sodium (mmol/L)
Item in comprehensive metabolic panel for safety assessment
Measured: 12 weeks
Total bilirubin (mg/dL)
Item in comprehensive metabolic panel for safety assessment
Measured: 12 weeks
Total protein (g/dL)
Item in comprehensive metabolic panel for safety assessment
Measured: 12 weeks
White blood cells (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 12 weeks
Red blood cells (x10E6/uL)
Item in complete blood count for safety assessment
Measured: 12 weeks
Hemoglobin (g/dL)
Item in complete blood count for safety assessment
Measured: 12 weeks
Hematocrit (%)
Item in complete blood count for safety assessment
Measured: 12 weeks
Mean corpuscular volume (fL)
Item in complete blood count for safety assessment
Measured: 12 weeks
Mean corpuscular hemoglobin concentration (g/dL)
Item in complete blood count for safety assessment
Measured: 12 weeks
Red cell distribution width (%)
Item in complete blood count for safety assessment
Measured: 12 weeks
Platelets (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 12 weeks
Neutrophils (%)
Item in complete blood count for safety assessment
Measured: 12 weeks
Monocytes (%)
Item in complete blood count for safety assessment
Measured: 12 weeks
Eosinophils (%)
Item in complete blood count for safety assessment
Measured: 12 weeks
Basophils (%)
Item in complete blood count for safety assessment
Measured: 12 weeks
Neutrophils (Absolute) (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 12 weeks
Lymphocytes (Absolute) (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 12 weeks
Monocytes (Absolute) (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 12 weeks
Eosinophils (Absolute) (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 12 weeks
Basophils (Absolute) (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 12 weeks
Immature granulocytes (%)
Item in complete blood count for safety assessment
Measured: 12 weeks
Immature granulocytes (Absolute) (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 12 weeks
Adverse events
This study will monitor the occurrence and frequency of adverse events and safety, both through participant report and blood chemistry/hematology/urine analyses.
Measured: 12 weeks
Generalized Anxiety Disorder-7 (GAD-7) scale
Validated, self-reported scale for the measurement of anxiety severity. The GAD-7 is a 7-item scale with total scores between 0 and 21. Higher scores indicate higher anxiety severity.
Measured: 12 weeks
Patient Health Questionnaire (PHQ-8) scale
Validated, self-reported scale for the measurement of depression severity. The PHQ-8 is an 8-item scale with total scores between 0 and 12. Higher scores indicate higher depression severity.
Measured: 12 weeks
Leeds Sleep Evaluation Questionnaire (LSEQ) scale
Validated, self-reported scale for the measurement of sleep quality. The LSEQ is a 10-item scale. Each item is scored 0 to 100. Higher scores indicate better sleep quality.
Measured: 12 weeks
Short Form-20 (SF-20) scale
Validated, self-reported scale for the assessment of subjective quality of life. The SF-20 is a 20-item scale. Each item is scored 0-100. Higher scores indicate better subjective quality of life.
Measured: 12 weeks
Digestion-associated Quality of Life Questionnaire (DQLQ)
Validated, self-reported scale for the measurement of digestion-associated quality of life outcomes. The DQLQ is a 9-item scale with total scores between 0 and 9. Each item is scored as a percentage 0-100, with 100 representing a score of 1. Higher scores indicate greater dissatisfaction with digestion-associated quality of life outcomes.
Measured: 12 weeks
Gastrointestinal Symptom Rating Scale (GSRS)
Validated, self-reported scale for the assessment of gastrointestinal symptoms and how much discomfort they cause. The GSRS consists of 15 items scored between 1 and 7 each. Higher scores indicate more severe symptoms.
Measured: 12 weeks
Digit Symbol Substitution Test (DSST)
A timed test that measures psychomotor performance and cognitive function. The test taker is given a key grid of numbers and matching symbols, and a list of numbers and empty boxes. The test taker matches the symbols to the numbers in the empty boxes within the allowed time (90 seconds). Participants will be scored according to the number of symbols they correctly correlate with a number.
Measured: 12 weeks
Word Recall Test (WRT)
A timed memory assessment that asks the test taker to recall a list of words. The test administrator reads a list of 15 words, and the test taker is asked to immediately write down all the words they remember. After 15 minutes, the test taker is asked to write down the words again. Participants will be scored based on the number of words they recall immediately and after 15 minutes.
Measured: 12 weeks
Functional movement test
Functional Movement Test (FMT) is an assessment used to evaluate an individual's movement patterns, mobility, stability, and overall functional fitness. It consists of several fundamental movement tests designed to identify weaknesses, imbalances, or limitations in a person's functional ability. During an FMT, a person is asked to perform movements such as directional neck movements, arm reaches, squats, push-ups, and balance on one leg. Each movement is scored based on form and control.
Measured: 12 weeks
Gut microbiome test
Participants complete stool collection kits. Stool is analyzed for gut microbiome composition (e.g. bacteria %/count/type)
Measured: 12 weeks
Total steps
Daily number of steps measured with fitness trackers.
Measured: 12 weeks
Sleep score
A personalized score, ranging from 1 to 100, that reflects quality of sleep based on factors like time asleep, deep and REM sleep.
Measured: 12 weeks
Body mass index (BMI)
A calculation of body fat based on height and weight
Measured: 12 weeks
Body mass percentage (%)
An estimation of bone, fat, muscle, and water mass %
Measured: 12 weeks
Blood pressure (mmHg)
The force of blood pushing against the walls of arteries.
Measured: 12 weeks
Heart rate (BPM)
The number of heart beats per minute
Measured: 12 weeks
Waist circumference (cm)
The circumference of the waist measured at the thinnest point of the waist
Measured: 12 weeks
Insulin (uIU/mL)
Serum marker used to determine insulin levels
Measured: 12 weeks
Sex hormone binding globulin (nmol/L)
Serum marker used to determine SHBG (Sex Hormone Binding Globulin) levels
Measured: 12 weeks
Testosterone (ng/dL)
Serum marker used to determine testosterone levels
Measured: 12 weeks
Thyroxine (T4) (ng/dL)
Serum marker used to determine thyroxine (T4) levels
Measured: 12 weeks
Thyroglobulin antibody (IU/mL)
Serum marker used to determine thyroglobulin antibody levels
Measured: 12 weeks
Thyroid peroxidase antibody (IU/mL)
Serum marker used to determine thyroid peroxidase antibody levels
Measured: 12 weeks
Vitamin B12 (pg/mL)
Serum marker used to determine Vitamin B12 levels
Measured: 12 weeks
Ferritin (ng/mL)
Serum marker used to determine ferritin levels
Measured: 12 weeks
Gamma-glutamyl transferase (GGT)
Serum marker used to determine GGT levels
Measured: 12 weeks
Transferritin saturation
Serum test used to determine UIBC, TIBC, Iron, Fe Saturation%
Measured: 12 weeks
Total sleep (minutes)
Total number of minutes asleep, as measured by fitness tracker.
Measured: 12 weeks
Light sleep (%)
The percentage of time asleep spent in light sleep, as measured by fitness tracker.
Measured: 12 weeks
Deep sleep (%)
The percentage of time asleep spent in deep sleep, as measured by fitness tracker.
Measured: 12 weeks
REM sleep (%)
The percentage of time asleep spent in deep sleep, as measured by fitness tracker.
Measured: 12 weeks
Active minutes
Number of daily active minutes as measured by fitness tracker.
Measured: 12 weeks
Sedentary minutes
Number of daily sedentary minutes as measured by fitness tracker.
Measured: 12 weeks
Active calories burned
Number of daily active calories burned as measured by fitness tracker.
Measured: 12 weeks
Total calories burned
Number of daily total calories burned as measured by fitness tracker.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2025
- Study start29 Apr 2025
- Primary completion3 Sep 2025
- Study completion3 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 97 participants (actual)
Sponsor and investigators
- Lead sponsor
- dōTERRA International
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Nicole Stevens, PhD, Principal investigator, doTERRA International LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06931977
- Sponsor's protocol ID
- DO-125023-FWS
- Status last verified
- Mar 2026
- First submitted
- 2 Apr 2025
- Last updated
- 10 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Wellness and Epigenetic Impact of a Natural Product Supplement System Combined With Lifestyle Modification
- ClinicalTrials.gov ID
- NCT06931977
- Acronym / sponsor ID
- DO-125023-FWS
- Conditions
- Healthy
- Keywords
- Gene expression, Essential oil, Copaiba, Omega 3, Probiotic, Greens powder
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 97 participants (actual)
- Lead sponsor
- dōTERRA InternationalIndustry (pharma, biotech, devices)
- Study start
- 29 Apr 2025 (actual)
- Primary completion
- 3 Sep 2025 (actual)
- Study completion
- 3 Sep 2025 (actual)
- First posted
- 17 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether four dietary supplements and lifestyle changes can affect gene expression and blood markers in healthy volunteers. The main questions it aims to answer are:
- How does daily ingestion of dietary supplements affect gene expression and hsCRP and vitamin D levels measured in blood?
- How does daily ingestion of dietary supplements affect anthropometric measurements, sleep and physical activity, and gut microbiome composition?
- How does daily ingestion of dietary supplements affect cognitive and subjective health parameters?
- Do prescriptive lifestyle modifications affect the supplements' efficacy?
- Is there a difference in outcomes between participants who take all four study supplements and those who take three study supplements with a placebo?
- Is ingesting dietary supplements for 12 weeks safe, as measured by laboratory tests and adverse events?
Detailed description
This double-blind, repeated measures study will recruit healthy adults to determine efficacy, safety, anthropometric, microbiome, and epigenetic effects of consuming four dietary supplements daily for 12 weeks. Prescriptive lifestyle modifications (diet, exercise, and sleep) will be evaluated with the supplement use.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Supplement System + Copaiba softgels | Experimental | Dietary Supplement: Supplement system + copaiba softgelsParticipants in this arm will take one VMG sachet, three EOM softgels, and one copaiba softgel in the morning with food. At least eight hours later, they will take one PBR capsule and one copabia softgel with food. They will follow this dosing regimen every day for 12 weeks. |
| Supplement System + placebo softgels | Placebo comparator | Dietary Supplement: Supplement system + placebo softgelsParticipants in this arm will take one VMG sachet, three EOM softgels, and one placebo softgel in the morning with food. At least eight hours later, they will take one PBR capsule and one placebo softgel with food. They will follow this dosing regimen every day for 12 weeks. |
Who may qualify
- Ages
- 30 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (24 listed)
- Adults ages 30-55 years old
- Willing to attend three study visits at Prime Meridian Health Clinic in Pleasant Grove, Utah
- Willing and able to undergo three blood draws over 12 weeks
- Willing to provide urine and stool samples three times over 12 weeks
- Willing to wash out of all internally consumed essential oils or botanical products for at least 2 weeks prior to starting the study, and willing to maintain the washout for the duration of the study (14 weeks).
Key exclusion criteria (1 listed)
- Failure to meet all listed inclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Supplement system + copaiba softgelsThe supplement system consists of: * dōTERRA VMG+ Whole-Food Nutrient Complex (VMG) sachets * dōTERRA EO Mega+ Essential Oil Omega Complex (EOM) softgels * dōTERRA PB Restore ProBiome Complex (PBR) capsules Which will also be taken with: • dōTERRA Copaiba Essential Oil (CEO) softgels VMG is a powdered nutritional drink packaged in individual sachets. The powder is a blend of food powders/extracts, vitamins and minerals, probiotics, essential oils, and sweeteners. EOM is a softgel containing fish oil and wild orange essential oil. PBR is a capsule containing a mix of pre-, pro-, and post-biotics and bacteriophages. CEO is a softgel containing Copaifera (copaiba) essential oil and extra virgin olive oil. Participants will also be asked to implement lifestyle changes. They will be asked to try to get at least 8 hours of sleep, eat at least three servings of fruit/vegetables daily, and exercise at least 30 minutes every day. | Dietary supplement | Supplement System + Copaiba softgels |
| Supplement system + placebo softgelsThe supplement system consists of: * dōTERRA VMG+ Whole-Food Nutrient Complex (VMG) sachets * dōTERRA EO Mega+ Essential Oil Omega Complex (EOM) softgels * dōTERRA PB Restore ProBiome Complex (PBR) capsules Which will also be taken with: • Olive oil placebo softgels VMG is a powdered nutritional drink packaged in individual sachets. The powder is a blend of food powders/extracts, vitamins and minerals, probiotics, essential oils, and sweeteners. EOM is a softgel containing fish oil and wild orange essential oil. PBR is a capsule containing a mix of pre-, pro-, and post-biotics and bacteriophages. The placebo is a softgel containing extra virgin olive oil. Participants will also be asked to implement lifestyle changes. They will be asked to try to get at least 8 hours of sleep, eat at least three servings of fruit/vegetables daily, and exercise at least 30 minutes every day. | Dietary supplement | Supplement System + placebo softgels |
Primary outcome
Gene expression
Time frame: 12 weeks
Gene expression analysis refers to a genome-wide quantification of methylation. EPIC850k array will be used for methylation analysis. This represents approximately 900,000 gene locations. The main feature performed is a differential methylation analysis to determine what has significantly changed from one time point to another.
Vitamin D 25-hydroxy (ng/mL)
Time frame: 12 weeks
Serum marker for Vitamin D levels
High sensitivity C-reactive protein (mg/L)
Time frame: 12 weeks
Serum marker for hsCRP levels
68 secondary outcomes
Albumin (g/dL)
Time frame: 12 weeks
Blood urea nitrogen (BUN) (mg/dL)
Time frame: 12 weeks
Creatinine (mg/dL)
Time frame: 12 weeks
Alkaline phosphatase (U/L)
Time frame: 12 weeks
Alanine transaminase (ALT) (U/L)
Time frame: 12 weeks
Aspartate aminotransferase (AST) (U/L)
Time frame: 12 weeks
Calcium (mg/dL)
Time frame: 12 weeks
Carbon Dioxide (mmol/L)
Time frame: 12 weeks
Chloride (mmol/L)
Time frame: 12 weeks
Potassium (mmol/L)
Time frame: 12 weeks
Sodium (mmol/L)
Time frame: 12 weeks
Total bilirubin (mg/dL)
Time frame: 12 weeks
Total protein (g/dL)
Time frame: 12 weeks
White blood cells (x10E3/uL)
Time frame: 12 weeks
Red blood cells (x10E6/uL)
Time frame: 12 weeks
Hemoglobin (g/dL)
Time frame: 12 weeks
Hematocrit (%)
Time frame: 12 weeks
Mean corpuscular volume (fL)
Time frame: 12 weeks
Mean corpuscular hemoglobin concentration (g/dL)
Time frame: 12 weeks
Red cell distribution width (%)
Time frame: 12 weeks
Platelets (x10E3/uL)
Time frame: 12 weeks
Neutrophils (%)
Time frame: 12 weeks
Monocytes (%)
Time frame: 12 weeks
Eosinophils (%)
Time frame: 12 weeks
Basophils (%)
Time frame: 12 weeks
Neutrophils (Absolute) (x10E3/uL)
Time frame: 12 weeks
Lymphocytes (Absolute) (x10E3/uL)
Time frame: 12 weeks
Monocytes (Absolute) (x10E3/uL)
Time frame: 12 weeks
Eosinophils (Absolute) (x10E3/uL)
Time frame: 12 weeks
Basophils (Absolute) (x10E3/uL)
Time frame: 12 weeks
Immature granulocytes (%)
Time frame: 12 weeks
Immature granulocytes (Absolute) (x10E3/uL)
Time frame: 12 weeks
Adverse events
Time frame: 12 weeks
Generalized Anxiety Disorder-7 (GAD-7) scale
Time frame: 12 weeks
Patient Health Questionnaire (PHQ-8) scale
Time frame: 12 weeks
Leeds Sleep Evaluation Questionnaire (LSEQ) scale
Time frame: 12 weeks
Short Form-20 (SF-20) scale
Time frame: 12 weeks
Digestion-associated Quality of Life Questionnaire (DQLQ)
Time frame: 12 weeks
Gastrointestinal Symptom Rating Scale (GSRS)
Time frame: 12 weeks
Digit Symbol Substitution Test (DSST)
Time frame: 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Healthy
Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
Active, not recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Recruiting
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Fatty Acids, Omega-3, Fish Oils
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nicole Stevens, PhD principal investigator
doTERRA International LLC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Supplement system + copaiba softgels in people with Healthy, run by dōTERRA International at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 24 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gene expression (time frame: 12 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2026.